Drug intelligence / Profile preview

Lingxiang Tablets

Development stage: Phase 2
Lead developer: Zhejiang Jolly Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Lingxiang Tablets (灵香片) is a Class 1.1 new Traditional Chinese Medicine (TCM) developed by Zhejiang Zolix Pharmaceutical Co., Ltd. It is specifically formulated for the treatment of chronic pelvic pain associated with the sequelae of pelvic inflammatory disease, particularly in patients diagnosed with the 'Kidney Deficiency and Blood Stasis' syndrome according to TCM principles. As a Class 1.1 new drug, it is derived from a clinical experience prescription and is intended to provide a standardized therapeutic option for chronic inflammatory pain in the pelvic region. The drug is currently undergoing Phase II clinical trials in China to evaluate its efficacy and safety in alleviating pain and improving the quality of life for affected patients.

Brand names: Lingxiang Tablets
Other names: Lingxiang Pian灵香片

Beyond the preview

Go deeper on Lingxiang Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lingxiang Tablets.